Navigation Links
GW Pharmaceuticals plc Reports 2013 Q4 and Full Year Financial Results

LONDON, Nov. 19, 2013 /PRNewswire/ -- GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW," "the Company" or "the Group"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announces its preliminary results for the fourth quarter and the year ended 30 September 2013.  


  • Initial public offering on the NASDAQ Global Market completed in May 2013 raising total net proceeds before expenses of $30.7m (£19.8m)
  • Two U.S.-targeted Sativex® Phase 3 pivotal programs advanced in 2013
  • Cancer Pain: two pivotal Sativex Phase 3 trials in recruitment
  • First Phase 3 top-line results expected in H2 2014
  • Data intended to lead to a New Drug Application (NDA) filing with the U.S. Food and Drug Administration (FDA)
  • Multiple Sclerosis (MS): Phase 3 Investigational New Drug (IND) application opened with the FDA for Sativex in the treatment of MS spasticity
  • Special Protocol Assessment (SPA) to be requested prior to anticipated start of Phase 3 trial in 2014
  • All Sativex Phase 3 clinical trials targeted at FDA approval are fully funded by U.S. partner, Otsuka
  • Sativex U.S. patent position further strengthened through two additional U.S. Notices of Allowance
  • Sativex now approved in 22 countries (ex-U.S) as a treatment for MS spasticity
  • In-market sales by partners increased by 25%
  • Commercial launch in Italy in July 2013
  • Germany pricing agreement reached in September 2013
  • Recommendation for approval in France in October 2013
  • On-going commercial launches in planning over next 12 months
  • New Sativex data presented at ECTRIMS in October 2013
  • Expansion of epilepsy research program through commencement of a new orphan pediatric epilepsy program for Epidiolex® (purified extract of Cannabidiol, or CBD)
  • FDA orphan drug designation granted by FDA for Epidiolex in Dravet syndrome
  • Seven physician-led INDs granted by FDA to treat 125 pediatric epilepsy patients in the U.S. with Epidiolex
  • Epidiolex pediatric epilepsy clinical trials in planning for 2014
  • Additional epilepsy pipeline candidate, GWP42006 (Cannabidivarin or CBDV), commenced Phase 1 trial in September 2013
  • Significant clinical activity for GW's other cannabinoid pipeline product candidates, including:
  • Positive preliminary data reported from a Phase 2a exploratory clinical trial of the novel cannabinoid medicine GWP42004 in type-2 diabetes with a Phase 2 dose ranging trial expected to commence in early 2014
  • Phase 2 trial of GWP42003 for the treatment of ulcerative colitis on-going with data expected in the first half of 2014
  • Phase 2 trial of GWP42003 for the treatment of schizophrenia expected to commence in the first half of 2014
  • Phase 1b/2a trial of THC:CBD for the treatment of glioma commenced in November 2013
  • Financial Highlights

  • Total revenue for 2013 of £27.3m ($44.2m) compared to £33.1m in 2012. 2012 revenues included a £9.8m milestone receipt compared to £0.3m milestone income in 2013.
  • Net loss after tax for 2013 of £4.5m ($7.4m) compared to a profit after tax of £2.5m in 2012, which primarily reflected the impact of the £9.8m milestone payment received last year.
  • Cash and cash equivalents at 30 September 2013 of £38.1m ($61.6m) compared to £29.3m as at 30 September 2012.
  • "This was a transformative year for GW with the successful completion of an IPO on NASDAQ, progress with two Phase 3 programs for Sativex in the United States, and the emergence of a new exciting orphan development program in childhood epilepsy," stated Justin Gover, GW's Chief Executive Officer. "We believe that the Company is poised to meet a number of significant clinical, regulatory and commercial milestones for GW investors. These include Phase 3 data from our U.S.-focused pivotal Sativex trials, further Sativex commercial launches and sales growth, progress of the new orphan epilepsy program in the U.S., and further advancement of several other cannabinoid pipeline candidates."

    Conference Call and Webcast InformationGW Pharmaceuticals will host a conference call and webcast to discuss the 2013 financial results today at 8:00 a.m. ET / 1:00 p.m. GMT. To participate in the conference call, please dial 877-407-8133 (toll free from the U.S. and Canada), or 0-800-756-3429 (toll free from the UK) or 201-689-8040 (international). Investors may also access a live audio webcast of the call via the investor relations section of the Company's website at A replay of the call will also be available through the GW website shortly after the call and will remain available for 30 days. Replay Numbers: (toll free):1-877-660-6853, (international):1-201-612-7415. For both dial-in numbers please use conference ID # 13572702.

    About GW Pharmaceuticals plcFounded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW commercialized the world's first plant-derived cannabinoid prescription drug, Sativex®, which is approved for the treatment of spasticity due to multiple sclerosis in 22 countries. Sativex is also in Phase 3 clinical development as a potential treatment of pain in people with advanced cancer. This Phase 3 program is intended to support the submission of a New Drug Application for Sativex in cancer pain with the U.S. Food and Drug Administration and in other markets around the world. GW has established a world leading position in the development of plant-derived cannabinoid therapeutics and has a deep pipeline of additional clinical-stage cannabinoid product candidates targeting epilepsy (including an orphan pediatric epilepsy program), type 2 diabetes, ulcerative colitis, glioma and schizophrenia. For further information, please visit

    Forward-looking statementsThis news release may contain forward-looking statements that reflect GWs current expectations regarding future events, including statements regarding financial performance, timing of clinical trials and data, relevance of GW products commercially available and in development, size of market opportunities, and development and regulatory clearance of GW's products. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, including (inter alia), the success of the GW's research strategies, the applicability of the discoveries made therein, the successful and timely completion of uncertainties related to the regulatory process, and the acceptance of Sativex® and other products by consumer and medical professionals. A further list and description of risks, uncertainties and other risks associated with an investment in GW can be found in GW's filings with the U.S. Securities and Exchange Commission, including the prospectus related to the NASDAQ offering filed by GW with the SEC on May 1, 2013. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. GW undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. GW Pharmaceuticals plc

    Consolidated income statement

    For the year ended 30 September 2013Year endedYear endedYear ended30 September30 September30 SeptemberNotes


    44,15827,29533,120Cost of sales(2,064)(1,276)(839)Research and development expenditure


    (52,897)(32,697)(27,578)Management and administrative expenses(6,135)(3,792)(3,660)Operating (loss)/profit(16,938)(10,470)1,043Interest expense(104)(64)(1)Interest income288178200(Loss)/profit before tax(16,754)(10,356)1,242Tax


    9,3955,8071,248(Loss)/profit for the year(7,359)(4,549)2,490(Loss)/earnings per share- basic7

    (4.9)c(3.0)p1.9p- diluted7

    (4.9)c(3.0)p1.8pAll activities relate to continuing operations.

    The Group has no gains or losses other than those shown above and therefore no separate statement of recognised income and expense has been presented.GW Pharmaceuticals plc

    Consolidated income statement

    For the three months ended 30 September 2013Three months

    endedThree months endedThree months

     ended30 September30 September30 September201320132012$000's£000's£000'sRevenue11,5217,1217,587Cost of sales(567)(351)(302)Research and development expenditure(14,827)(9,165)(9,182)Management and administrative expenses(1,684)(1,041)(693)Operating loss(5,557)(3,436)(2,590)Interest payable(31)(19)-Interest income1086759Loss on ordinary activities before taxation(5,480)(3,388)(2,531)Tax credit on ordinary activities1,191736320Loss on ordinary activities after taxation(4,289)(2,652)(2,211)Loss per share- basic(2.4)c(1.5)p(1.7)p- diluted(2.4)c(1.5)p(1.7)p GW Pharmaceuticals plc

    Consolidated balance sheet

    As at 30 September 201330 September30 September30 SeptemberNotes

    201320132012$000's£000's£000'sNon-current  assetsIntangible assets - goodwill8,4295,2105,210Property, plant & equipment8,8595,4762,43217,28810,6867,642Current assetsInventories


    7,5414,6613,537Deferred tax asset1,447895–Taxation recoverable4,6922,900820Trade and other receivables


    2,8041,7331,588Cash and cash equivalents61,58838,06929,33578,07248,25835,280Total assets95,36058,94442,922Current liabilitiesTrade and other payables


    (15,272)(9,440)(9,114)Obligations under finance leases


    (162)(100)–Deferred revenue


    (5,146)(3,181)(2,449)(20,580)(12,721)(11,563)Non-current liabilitiesObligations under finance leases


    (3,082)(1,905)–Deferred revenue


    (14,424)(8,916)(10,127)Total liabilities(17,506)(23,542)(21,690)Net assets57,27435,40221,232EquityShare capital


    288178133Share premium account135,90384,00565,947Other reserves32,65420,18420,184Retained earnings (111,571)(68,965)(65,032)Shareholders' funds57,27435,40221,232This announcement was approved by the Board of Directors on 18 November 2013.GW Pharmaceuticals plc

    Consolidated cash flow statement

    For the year ended 30 September 2013Year endedYear endedYear ended30 September30 September30 September201320132012$000's£000's£000's(Loss)/profit for the year(7,359)(4,549)2,490Adjustments for:Interest expense

    104641Interest income


    (9,395)(5,807)(1,248)Depreciation of property, plant and equipment

    1,600989754Net foreign exchange (gains) / losses

    (40)(25)(202)(Decrease)/increase in allowance for doubtful debts

    (42)(26)26Decrease in inventory provision

    (857)(530)(1,300)Share-based payment charge

    9976161,009(15,280)(9,446)1,330Increase in inventories

    (961)(594)(813)(Increase) / decrease in trade receivables and other assets

    (175)(108)609(Decrease) / increase in trade and other payables and deferred revenue

    (246)(152)247Cash (used in)/generated by operations(16,662)(10,300)1,373Research and development tax credits received

    4,5822,832428Net cash (outflow)/inflow from operating activities(12,080)(7,468)1,801Investment activitiesInterest received

    270167258Purchases of property, plant and equipment

    (3,629)(2,243)(1,318)Net cash outflow from investing activities(3,359)(2,076)(1,060)Financing activitiesProceeds on exercise of share options

    5381Proceeds of new equity issue

    31,98419,770–Expenses of new equity issue

    (2,702)(1,670)–Interest paid

    (104)(64)(1)Proceeds from finance leases

    364225–Capital element of finance leases

    (18)(11)(7)Net cash from financing activities29,52918,25373Effect of foreign exchange rate changes

    4025202Net increase in cash and cash equivalents14,1308,7341,016Cash and cash equivalents at beginning of year

    47,45829,33528,319Cash and cash equivalents at end of year61,58838,06929,335 

    SOURCE GW Pharmaceuticals plc
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
    2. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
    3. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
    4. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
    5. Icahn Issues Statement Regarding Amylin Pharmaceuticals
    6. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
    7. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
    8. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
    9. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
    10. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
    11. Avanir Pharmaceuticals To Present at Three Conferences In May
    Post Your Comments:
    (Date:9/19/2017)...   ZirMed Inc ., a recognized leader in cloud-based ... has been ranked #1 by its users for the seventh ... User Survey. ZirMed was recognized as the top-ranked end-to-end revenue ... centers over 200 beds and holds one of the longest ... history. ...
    (Date:9/13/2017)... , Sept. 13, 2017   OrthoAtlanta has been ... Atlanta Football Host Committee (AFHC) for the 2018 College Football ... 8, 2018, at Mercedes-Benz Stadium in Atlanta, Georgia ... the AFHC "I,m In" campaign, participating in many activities leading ... ...
    (Date:9/12/2017)... Sept. 12, 2017  ValGenesis Inc., the global ... is pleased to announce the appointment of Dr. ... its Board of Directors and Chairman of Advisory ... life science companies to manage their entire validation ... paper in this process. Furthermore, ValGenesis VLMS enables ...
    Breaking Medicine Technology:
    (Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and ... apnea using cutting-edge Oventus O2Vent technology. As many as 18 million Americans ... frequent cessation in breathing. Oral appliances can offer significant relief to about 75 ...
    (Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( ), ... of an innovative new design of the shoulder pad. The shoulder pad provides ... while controlling your pain while using cold therapy. By utilizing ice and water that ...
    (Date:10/12/2017)... Rockville, Maryland (PRWEB) , ... October 12, 2017 ... ... a magnetic drug delivery system that we intend to develop to enable prevention ... regimens can lead to severe hearing loss, especially in pediatric patients. For cisplatin, ...
    (Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at Children’s National ... 49th Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. ... for Cancer and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., ...
    (Date:10/12/2017)... ... October 12, 2017 , ... Health Literacy Innovations (HLI), ... software tool, and the Cancer Patient Education Network (CPEN), an independent professional organization ... a new strategic alliance. , As CPEN’s strategic partner, HLI will help ...
    Breaking Medicine News(10 mins):